Koyfin Home > Directory > Health Care > Adma Biologics > EBITDA / Interest Expenses

Adma Biologics EBITDA / Interest Expenses Chart (ADMA)

Adma Biologics annual/quarterly EBITDA / Interest Expenses from 2010 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Adma Biologics EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-5m a 41.66% decrease of -2m year over year
  • Adma Biologics EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-4m a -45.84% increase of 2m year over year
  • Adma Biologics Annual EBITDA / Interest Expenses for 2019 was $-4m a -146.40% increase of 6m from 2018
  • Adma Biologics Annual EBITDA / Interest Expenses for 2018 was $-10m a -14.94% increase of 2m from 2017
  • Adma Biologics Annual EBITDA / Interest Expenses for 2017 was $-12m a 36.36% decrease of -4m from 2016
Other Ratios Metrics:
  • Adma Biologics Total Debt / Capital for the quarter ending September 09, 2018 was $53m a 4.96% increase of 3m year over year
  • Adma Biologics Other Liabilities for the quarter ending December 12, 2018 was $18m a -0.86% decrease of 0m year over year
  • Adma Biologics Total Debt / Equity for the quarter ending September 09, 2018 was $111m a 9.91% increase of 11m year over year
View Chart On Koyfin

Quarterly ADMA EBITDA / Interest Expenses Data

06/2020$-5m
03/2020$-6m
12/2019$-3m
09/2019$-3m
06/2019$-5m
03/2019$-8m
12/2018$-11m
09/2018$-9m
06/2018$-9m
03/2018$-12m

Annual ADMA EBITDA / Interest Expenses Data

2019$-4m
2018$-10m
2017$-12m
2016$-8m
2015$-8m
2014$-12m
2013$-24m
2012$-252m
2011$-2m
2010$-7m